Home
My Learning
My
The demand for healthcare services is fundamentally stable, as everyone needs medical care regardless of the economy. XLV, one of the largest healthcare ETFs, includes some of the most prominent companies in the U.S. healthcare sector. Today, let’s discuss whether XLV is a worthwhile investment.
XLV, officially known as the Health Care Select Sector SPDR Fund, was established in 1998 and tracks the performance of the healthcare sector index within the S&P 500.
Total Assets: $41.62 billion
Dividend Yield: 1.48% (quarterly dividends)
Management Fee: 0.09%
Number of Holdings: 62
Inception Date: December 16, 1998
|
Companies |
Weight (%) |
|
Eli Lilly (LLY) |
12.41 |
|
UnitedHealth Group (UNH) |
9.58 |
|
Johnson & Johnson (JNJ) |
6.93 |
|
AbbVie (ABBV) |
6.19 |
|
Merck & Co. (MRK) |
5.17 |
|
Thermo Fisher Scientific (TMO) |
4.16 |
|
Abbott Laboratories (ABT) |
3.51 |
|
Danaher Corporation (DHR) |
3.14 |
|
Amgen (AMGN) |
3.06 |
|
Intuitive Surgical (ISRG) |
3.06 |
XLV mainly tracks the healthcare sector of the S&P 500 index and features several prominent companies, including UnitedHealth Group, Eli Lilly, Johnson & Johnson, Merck & Co., and AbbVie. These firms are leaders in the healthcare industry with stable operations, offering a strong foundation for XLV.
All Comments